These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

773 related articles for article (PubMed ID: 32711449)

  • 1. Differentiation of soft tissue and bone sarcomas from benign lesions utilizing
    Chen B; Feng H; Xie J; Li C; Zhang Y; Wang S
    BMC Med Imaging; 2020 Jul; 20(1):85. PubMed ID: 32711449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of (18)F-FDG PET at diagnosis in patients with soft tissue sarcoma and bone sarcoma; systematic review and meta-analysis.
    Kubo T; Furuta T; Johan MP; Ochi M
    Eur J Cancer; 2016 May; 58():104-11. PubMed ID: 26990930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Volume-based parameters on FDG PET may predict the proliferative potential of soft-tissue sarcomas.
    Kitao T; Shiga T; Hirata K; Sekizawa M; Takei T; Yamashiro K; Tamaki N
    Ann Nucl Med; 2019 Jan; 33(1):22-31. PubMed ID: 30196378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total lesion glycolysis by 18F-FDG PET/CT is a reliable predictor of prognosis in soft-tissue sarcoma.
    Choi ES; Ha SG; Kim HS; Ha JH; Paeng JC; Han I
    Eur J Nucl Med Mol Imaging; 2013 Dec; 40(12):1836-42. PubMed ID: 23880967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical value of texture analysis of dual-time-point
    Nakajo M; Jinguji M; Aoki M; Tani A; Sato M; Yoshiura T
    Eur Radiol; 2020 Mar; 30(3):1759-1769. PubMed ID: 31728684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions.
    Ciftci E; Turgut B; Cakmakcilar A; Erturk SA
    Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Semi-Quantitative Calculations of Primary Tumor Metabolic Activity Using F-18 FDG PET/CT as a Predictor of Survival in 92 Patients With High-Grade Bone or Soft Tissue Sarcoma.
    Andersen KF; Fuglo HM; Rasmussen SH; Petersen MM; Loft A
    Medicine (Baltimore); 2015 Jul; 94(28):e1142. PubMed ID: 26181552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Volume-Based F-18 FDG PET/CT Imaging Markers Provide Supplemental Prognostic Information to Histologic Grading in Patients With High-Grade Bone or Soft Tissue Sarcoma.
    Andersen KF; Fuglo HM; Rasmussen SH; Petersen MM; Loft A
    Medicine (Baltimore); 2015 Dec; 94(51):e2319. PubMed ID: 26705220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of positron emission tomography/computed tomography (PET/CT) imaging in the evaluation of sarcomas: A systematic review.
    Lim HJ; Johnny Ong CA; Tan JW; Ching Teo MC
    Crit Rev Oncol Hematol; 2019 Nov; 143():1-13. PubMed ID: 31449981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment tumor SUV
    Ha SC; Oh JS; Roh JL; Moon H; Kim JS; Cho KJ; Choi SH; Nam SY; Kim SY
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):33-40. PubMed ID: 27448574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-Analysis of the Diagnostic Accuracy of Primary Bone and Soft Tissue Sarcomas by 18F-FDG-PET.
    Younis MH; Abu-Hijleh HA; Aldahamsheh OO; Abualruz A; Thalib L
    Med Princ Pract; 2020; 29(5):465-472. PubMed ID: 31887730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of soft-tissue lesions with (18)F-FDG PET/CT: initial results of a prospective trial.
    Leal AL; Etchebehere M; Santos AO; Kalaf G; Pacheco EB; Amstalden EM; Etchebehere EC
    Nucl Med Commun; 2014 Mar; 35(3):252-9. PubMed ID: 24300379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of Volumetric Parameters Measured by Pretreatment 18F FDG PET/CT in Patients With Cutaneous Malignant Melanoma.
    Son SH; Kang SM; Jeong SY; Lee SW; Lee SJ; Lee J; Ahn BC
    Clin Nucl Med; 2016 Jun; 41(6):e266-73. PubMed ID: 27055144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions.
    Xu R; Kido S; Suga K; Hirano Y; Tachibana R; Muramatsu K; Chagawa K; Tanaka S
    Ann Nucl Med; 2014 Nov; 28(9):926-35. PubMed ID: 25107363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Value of Volume-Based Fluorine-18-Fluorodeoxyglucose PET/CT Parameters for Characterizing Thyroid Incidentaloma.
    Shi H; Yuan Z; Yuan Z; Yang C; Zhang J; Shou Y; Zhang W; Ping Z; Gao X; Liu S
    Korean J Radiol; 2018; 19(2):342-351. PubMed ID: 29520193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The diagnostic and prognostic value of ¹⁸F-FDG PET/CT in the initial assessment of high-grade bone and soft tissue sarcoma. A retrospective study of 89 patients.
    Fuglø HM; Jørgensen SM; Loft A; Hovgaard D; Petersen MM
    Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1416-24. PubMed ID: 22699526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic ability of [
    Lee DY; Kim YI; Ryu JS
    Eur Radiol; 2024 Jul; ():. PubMed ID: 39026061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
    Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
    Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic performance of
    Altinmakas E; Hobbs BP; Ye H; Grubbs EG; Perrier ND; Prieto VG; Lee JE; Ng CS
    Abdom Radiol (NY); 2017 Feb; 42(2):577-584. PubMed ID: 27665482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.